| Symbol | FATE |
|---|---|
| Name | FATE THERAPEUTICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA 92131 |
| Telephone | 858.875.1803 |
| Fax | — |
| — | |
| Website | https://www.fatetherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001434316 |
| Description | Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The companys cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. Additional info from NASDAQ: |
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Read moreFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read moreFate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
Read moreFate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Read more📋 Valamehr Bahram (Officer) plans to sell 29K shares of FATE THERAPEUTICS INC (at $1.88 each, total $54K) Filed: May 20, 2026 | ID: 003833
Read more📋 TAHL CINDY (Officer) plans to sell 26K shares of FATE THERAPEUTICS INC (at $1.88 each, total $48K) Filed: May 20, 2026 | ID: 003832
Read more(10% Negative) FATE THERAPEUTICS INC (FATE) Announces Delay in results Trials for broad accessibility Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreFate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Read moreFate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
Read moreTAHL CINDY 🟡 adjusted position in 0 shares (2 derivative) of FATE THERAPEUTICS INC (FATE) at $1.32 Transaction Date: May 06, 2026 | Filing ID: 211820
Read more